FINALS: MOLECULAR ONCOLOGY Flashcards

(35 cards)

1
Q

study of tumors/neoplasm (growth of tissue that exceeds and is not coordinated with normal tissue).

A

Oncology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

not recurrent; suffix -oma to the tissue of origin

A

Benign

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

invasive and tending to recur at multiple sites (cancer)

A

Malignant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

movement of tumor cells from the original (primary) site of the
tumor to other locations

A

Metastasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

study of cancer at the molecular level

A

Molecular Oncology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

a term that includes
all malignant tumors.

A

CANCER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CANCER:
an ABNORMAL MASS OF TISSUE that usually does not contain cysts or liquid areas

A

Solid tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SOLID TUMORS CANCER:
tumor of EPITHELIAL TISSUE origin

A

Carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

SOLID TUMORS CANCER:
tumor of BONE, CARTILAGE, muscle, blood vessel, or fat

A

Sarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

SOLID TUMORS CANCER:
- consists of multiple cell types
- Common among them is that they are capable of formation of ___________

A

Teratocarcinoma

  • angiogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CANCER:
ABNORMAL CELLS in the blood grow out of control

A

Hematological malignancies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hematological malignancies CANCER:

  • neoplastic disease of blood-forming tissue in which large number of WBCs populate the bone marrow and peripheral blood
A

Leukemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Hematological malignancies CANCER:

  • neoplasm of lymphocytes that forms discrete tissue masses
    i. Usually accumulates in the lymph nodes
    ii. Purkitt’s lymphoma
A

Lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
  • arise from terminally differentiated B cells
  • abnormal plasma cells or cells from tumors in the bones/soft tissues of the body
A

Plasma cell neoplasms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cancer is caused by ________ mutations in DNA affecting 2 types of genes that control the cell division cycle and cell survival: ONCOGENES AND TUMOR SUPPRESSOR GENES

A

nonlethal mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
  • Promote cell division
  • Include cell membrane receptors that are
    bound by growth factors, hormones, and
    other extracellular signals
  • Support cell survival by inhibiting apoptosis
  • > 100 in the human genome
  • Gain-of-function mutations resulting from
    ○ Amplification /translocation of DNA regions containing genes
    ○ Activating mutations that cause aberrant activity of the proteins
17
Q
  • Factors that control transcription/translation of genes required for cell division
  • Participate in repairing DNA damage and in
    promoting apoptosis
  • Slow down/stop cell division by counteracting the movement of the cell from G1-to S (G1
    checkpoint) or G2 to M phase (G2 checkpoint)
  • > 30 in the human genome
  • Loss-of-function mutations
    ○ Inactivation of the gene products (deletion, translocation, mutation of the genes)
    ~ Ex. p53
A

Tumor-suppressor genes

18
Q

ANALYTICAL TARGETS OF MOLECULAR TESTING
- Molecular characteristics of the tissue from which a tumor arose
- Detection and monitoring the presence of
tumor
○ Abnormal amounts or locations of DNA, RNA, proteins and other
molecules from these targets
○ Examples: DNA & RNA from
a. CYTOKERATIN genes from gastric cancer
b. CARCINOEMBRYONIC ANTIGEN in breast cancer

A

Tissue-Specific Targets

19
Q

ANALYTICAL TARGETS OF MOLECULAR TESTING
- Genetic structures resulting from mutations in oncogenes and tumor-suppressor genes that are associated with tumor development
- Solid tumors, leukemias, lymphomas
- Mutated cell-free nucleic acid/circulating
tumor cells can be detected in blood and
other body fluids

A

Tumor-Specific Targets

20
Q

group of tumors arising from primitive neuroectodermal tissue

Diagnosis and prognosis:
1. cytogenetic methods
2. molecular methods:
RT-PCR, with amplification control
(GAPDH or 185 RNA)
on tissue/liquid biopsies

A

Ewing Sarcoma, EWS
(22q12)

21
Q

rare type of cancer of the muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body

Detection methods:
1. FISH
2. RT-PCR
3. Semi-nested PCR
4. Agarose gel
electrophoresis & EtBr
staining (PCR product
detection)

A

SYNOVIAL SARCOMA
translocation, chrmosome 18 -Synopvial sarcoma, breakpoint 1 & 2, SYT-
SSX1, SYT-SSX2 t(X;18)
(p11.2;q11.2)

22
Q

most common soft tissue sarcoma of childhood (10% of all solid tumors in children)
➢ Alveolar RMS,
embryonal (RMS-E),
& primitive (RMS-P)all solid tumors in children)
➢ Alveolar RMS,
embryonal (RMS-E),
& primitive (RMS-P)

Detection methods: FISH, RT-PCR, qPCR, RNA
sequencing

A

Rhabdomyosarcoma (RMS)

23
Q

● Contraction & expansion of nucleotide repeat sequences in DNA
● Cause: dysfunction of 1 or more components of mismatch repair (MMR) systems

A

MICROSATELLITE INSTABILITY (MSI)

24
Q

recommended the screening of BAT25 & BAT26: & D5S346,
D25123, & D175250 for MSI determination

A

National Cancer Institute

25
● Deletion/inactivation of a functional allele, leaving a mutated allele ● Detection methods: ○ PCR & capillary electrophoresis: amplification of heterozygous STR/VNTR loci closely linked to the disease gene
LOSS OF HETEROZYGOSITY
26
● A laboratory test done on a sample of blood (plasma/serum), urine, or other body fluid to look for cells & nucleic acids released by the tumors into a person's body fluids
LIQIOD BIOPSY
27
● Series of intrachromosomal recombination events mediated by recombinase enzymes that recognize specific sequences flanking the gene segments ● Very common in immune cells, especially lymphocytes
Gene Rearrangements
28
Normal intrachromosomal breaking & joining of DNA in the genes coding for immunoglobulins and T-cell receptors
V(D)J recombination
29
● Gene encoding the immunoglobulin heavy chain is located on chromosome 14 ● As B lymphocytes mature, selected gene segments are joined together so that the rearranged gene contains only 1 of each V (variable). D (diversity) & J (joining) gene segments
Immunoglobulin heavy-chain gene rearrangement in B cells
30
● Genes encoding the lg light chains: kappa locus (chromosome 2) & lambda locus (chromosome 22) ● Rearranged in a kappa-before-lambda order
Immunoglobulin light-chain gene rearrangement in B cells
31
● T-cell receptor: 2 of 4 chains (α, β. γ & δ) with characteristic structures resembling Ig V. J. & C regions ○ α & δ chains: chromosome 14 ○ Β & γ chains: chromosome 7 ● V regions undergo gene rearrangement by intrachromosomal recombination ● V. (D). & J segments are joined together with the addition/deletion (trimming) of nucleotides at the junctions between the gene segments
T-cell receptor gene rearrangement
32
MUTATIONS IN HEMATOLOGICAL MALIGNANCIES: - t(14;18)(q32;q21) Detection methods: ● Southern Blot ● PCR or qPCR with gel electrophoresis or qPCR probe
Follicular lymphoma
33
MUTATIONS IN HEMATOLOGICAL MALIGNANCIES: - t(11;14)(q13;q32) Detection methods: ● Southern Blot ● PCR and RT-PCR with gel/capillary electrophoresis ● FISH or flow cytometry analysis
Mantle cell lymphoma, chronic lymphocytic leukemia, B-prolymphocytic Teukemia, plasma cell leukemia, multiple myeloma, splenic lymphoma
34
MUTATIONS IN HEMATOLOGICAL MALIGNANCIES: - t(8:14)(q24:q11) Detection methods ● Southern blot, using a 32p or digoxigenin- labeled 1.4 kb Cla1-EcoR1 restriction fragment ● Interphase FISH & CISH ● IHC: Myc protein expression
Burkitt lymphoma
35
MUTATIONS IN HEMATOLOGICAL MALIGNANCIES: - t(15:17)(q22:q11.2- q12) - Fusion of the retinoic acid receptor alpha (RARA) gene on chromosome 15 w/ the myelocytic leukemia (MYL) gene on chromosome 17 Detection Methods ● RT-PCR ● RT-qPCR
Promyelocytic leukemia